(Q36184231)

12 August 2017

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. (English)

1 reference

12 August 2017

14

1 reference

12 August 2017

20

1 reference

12 August 2017

30

1 reference

12 August 2017

33

M Cheang

1 reference

12 August 2017

K Pylkäs

17

0 references

Emad A. Rakha

E Rakha

24

0 references

Gianluca Severi

G Severi

15

0 references

Melissa C. Southey

M Southey

29

0 references

Ian Ellis

I Ellis

18

0 references

Fergus J. Couch

23

F J Couch

1 reference

12 August 2017

22

P A Fasching

1 reference

12 August 2017

31

A Mannermaa

1 reference

12 August 2017

13

R Winqvist

1 reference

12 August 2017

12

M W Beckmann

1 reference

12 August 2017

35

C Caldas

1 reference

12 August 2017

Montserrat García-Closas

36

M Garcia-Closas

1 reference

12 August 2017

21

C Blomqvist

1 reference

12 August 2017

32

A Cox

1 reference

12 August 2017

37

P D P Pharoah

1 reference

12 August 2017

William David Foulkes

25

W D Foulkes

1 reference

12 August 2017

34

L Baglietto

1 reference

12 August 2017

11

J E Olson

1 reference

12 August 2017

5

M K Schmidt

1 reference

12 August 2017

19

T O Nielsen

1 reference

12 August 2017

G C Wishart

1

1 reference

12 August 2017

C D Bajdik

2

1 reference

12 August 2017

E Dicks

3

1 reference

12 August 2017

E Provenzano

4

1 reference

12 August 2017

M Sherman

6

1 reference

12 August 2017

D C Greenberg

7

1 reference

12 August 2017

A R Green

8

1 reference

12 August 2017

K A Gelmon

9

1 reference

12 August 2017

V-M Kosma

10

1 reference

12 August 2017

D Huntsman

16

1 reference

12 August 2017

F M Blows

26

1 reference

12 August 2017

L R Bégin

27

1 reference

12 August 2017

L J van't Veer

28

1 reference

12 August 2017

language of work or name

English

0 references

publication date

31 July 2012

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

107

1 reference

12 August 2017

5

1 reference

12 August 2017

800-807

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2012.338

12 August 2017

0 references

cites work

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

A prognostic index in primary breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Confirmation of a prognostic index in primary breast cancer.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Independent prognostic value of screen detection in invasive breast cancer.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

A recurrent mutation in PALB2 in Finnish cancer families.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Association of a common variant of the CASP8 gene with reduced risk of breast cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Risk for distant recurrence of breast cancer detected by mammography screening or other methods

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

The Melbourne Collaborative Cohort Study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425970

Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses

21 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.338

Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.338

Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution

21 January 2018

1 reference

12 December 2020

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

1 reference

12 December 2020

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying theCHEK2*1100delCGermline Mutation

1 reference

12 December 2020

Reading the prognosis of the individual with breast cancer

1 reference

12 December 2020

Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999

1 reference

12 December 2020

Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients

1 reference

12 December 2020

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

12 December 2020

A population-based validation of the prognostic model PREDICT for early breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2012.338

1 reference

12 August 2017

1 reference

12 August 2017

1 reference